Stevanato Group S.p.A.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Franco Stevanato
- Full Time Employees
- 6,010
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- Via Molinella, 17 Piombino Dese PD Italy 35017
- IPO Date
- Jul 16, 2021
- CIK
- 0001849853
- Website
- stevanatogroup.com
- Similar Companies
- Business
- Stevanato Group S.p.A. (NYSE: STVN) provides integrated drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries; it operates through two segments, Biopharmaceutical and Diagnostic Solutions, and Engineering, delivering products, processes, and services across the drug life cycle from development to commercialization stages. The company manufactures advanced glass primary packaging under brands such as Ompi, including pre-fillable syringes, vials, cartridges, and ampoules; its EZ-fill pre-sterilized platform; drug delivery systems comprising pen injectors, auto-injectors, wearable injectors, and inhalers; in-vitro diagnostic consumables and medical components; visual inspection systems; assembly, packaging, and glass converting equipment; analytical testing services for container-drug interactions; and contract development and manufacturing for drug delivery devices. Founded in 1949 and headquartered in Piombino Dese, Italy, Stevanato Group maintains a global footprint with facilities across Europe, North America, South America, the Middle East, Africa, and Asia Pacific, including recent expansions such as a new manufacturing hub in Fishers, Indiana, USA, for drug containment and delivery production, and a €200 million financing package in 2025 to bolster capacity in Cisterna di Latina, Italy, and Fishers. In 2025, the company launched the ITC Syringe with Enlarged Inner Cone for enhanced intravenous drug delivery compatibility, expanded drug delivery systems capacity at its German facility to support scalable self-injection technologies, reported third-quarter revenue of €303.2 million reflecting robust growth, and formed the Alliance for RTU with SCHOTT Pharma and Gerresheimer to promote ready-to-use vials and cartridges among contract manufacturers. Stevanato Group, a subsidiary of Stevanato Holding S.R.L., serves pharmaceutical firms, biotech companies, diagnostics providers, and contract manufacturers focused on biologics, injectables, and mRNA therapies.
Company News
STVN Investors Have Opportunity to Join Stevanato Group S.p.A. Fraud Investigation with SBS Law
STVN INVESTOR ALERT: Investigation of Stevanato Group S.p.A. Announced by Holzer & Holzer, LLC
Lost Money on Stevanato Group S.p.A. Shares? The Law Offices of Frank R.
Lost Money on Stevanato Group S.p.A. Stock? Glancy Prongay Wolke & Rotter LLP Investigates Possible Securities Fraud After 28.57% Share Price Drop
Did You Lose Money on Stevanato Group S.p.A. Stock? The Law Offices of Howard G.
Stevanato Group (STVN) Shareholder Investigation Following Stock Decline – Kehoe Law Firm, P.C.
Stevanato Group Q3 Earnings Call Highlights
Stevanato Group S.p.A. Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Stevanato Group S.p.A.
Stevanato Group S.p.A. (STVN) Q3 2026 Earnings Call Transcript
Stevanato Group (STVN) Surpasses Q3 Earnings and Revenue Estimates
Stevanato Group Delivers 8% Revenue Growth for the Third Quarter of Fiscal 2026
Conestoga Small Cap Composite Q3 2026 Portfolio Activity
Stevanato Group and Aptar Pharma Collaborate to Help Accelerate Pre-Filled Syringe System Selection
Riverwater Partners Sustainable Value Strategy Q3 2026 Portfolio Update
Stevanato Group to Report Third Quarter 2026 Financial Results on November 3, 2026
Stevanato Group S.p.A. (STVN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Stevanato Group to Participate in Two Upcoming Investor Conferences
A Look at Stevanato Group SpA (STVN) After 3.4% Decline -- GF Value $25.98 vs Price $20.71
Stevanato Group: Alina Validates The Container-To-Device Flywheel
Stevanato Group SpA (STVN) Shares Fall 5.7% -- What GF Score of 87 Tells Investors